Molgramostim
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Pulmonary Alveolar Proteinosis
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Trial Timeline
Apr 16, 2018 → Jan 14, 2021
NCT ID
NCT03482752About Molgramostim
Molgramostim is a phase 3 stage product being developed by Savara for Autoimmune Pulmonary Alveolar Proteinosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03482752. Target conditions include Autoimmune Pulmonary Alveolar Proteinosis.
What happened to similar drugs?
0 of 12 similar drugs in Autoimmune Pulmonary Alveolar Proteinosis were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06431776 | Phase 3 | Recruiting |
| NCT03482752 | Phase 3 | Terminated |
Competing Products
20 competing products in Autoimmune Pulmonary Alveolar Proteinosis